A review of bioreactor protocols for human neural precursor cell expansion in preparation for clinical trials

Current Stem Cell Research and Therapy

Volumn 6, Issue 3, 2011, Pages 229-254

  Baghbaderani, Behnam A ^a   Mukhida, Karim ^b   Hong, Murray ^b   Mendez, Ivar ^b   Behie, Leo A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bioreactor expansion; Cell therapy; Long term expansion; Neural precursor cells; Neurodegenerative disorders; Neurogenic differentiation

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CELL SURFACE MARKER; EPIDERMAL GROWTH FACTOR; LEUKEMIA INHIBITORY FACTOR; OXYGEN; PRASTERONE;

ARTICLE; BIOREACTOR; CELL DIFFERENTIATION; CELL EXPANSION; CELL FATE; CELL ISOLATION; CELL RENEWAL; CELL SURFACE; CULTURE MEDIUM; CULTURE TECHNIQUE; HUMAN; HYDRODYNAMICS; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROCESS CONTROL;

ANIMALS; ANTIGENS, SURFACE; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; CULTURE MEDIA; DRUG DELIVERY SYSTEMS; HUMANS; NEURAL STEM CELLS; NEURODEGENERATIVE DISEASES; TIME-LAPSE IMAGING;

EID: 80051808144     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811796575378     Document Type: Article

References (248)

1. Storch A, Schwarz J. Neural stem cells and neurodegeneration. Curr Opin Investig Drugs 2002; 3: 774-81.
2. Dunnett SB, Rosser AE. Cell transplantation for Huntington's disease: Should we continue? Brain Res Bull 2007; 72: 132-47.
3. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 1137-40.
4. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574-7.
5. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-80.
6. Piccini P, Lindvall O, Bjorklund A, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000; 48: 689-95.
7. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19: 102-109.
8. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-24.
9. Mendez I, Dagher A, Hong M, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg 2002; 96: 589-96.
10. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005; 128: 1498-510.
11. Mendez I, Vinuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14: 507-9.
12. Dunnett SB, Rosser AE. Cell therapy in Huntington's disease. NeuroRx 2004; 1: 394-405.
13. Master Z, McLeod M, Mendez I. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. J Med Ethics 2007; 33: 169-73.
14. Carpenter MK, Inokuma MS, Denham J, et al. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol 2001; 172: 383-97.
15. Okano H. Neural stem cells: progression of basic research and perspective for clinical application. Keio J Med 2002; 51: 115-28.
16. Correia AS, Anisimov SV, Li JY, et al. Stem cell-based therapy for Parkinson's disease. Ann Med 2005; 37: 487-98.
17. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004; 10 Suppl: S42-50.
18. Miller RH. The promise of stem cells for neural repair. Brain Res 2006; 1091: 258-64.
19. Kim SU. Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev 2007; 29: 193-201.
20. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: A review. J Neurosci Res 2009; 87: 2183-200.
21. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 2006; 441: 1094-1096.
22. Orlacchio A, Bernardi G, Orlacchio A, et al. Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases. Curr Med Chem 2010; 17(7): 595-608.
23. Buc-Caron M-H. Neuroepithelial progenitor cells explanted from human fetal brain proliferate and differentiatein vitro. Neurobiol Dis 1995; 2: 37-47.
24. Chalmers-Redman RME, Priestley T, Kemp JA, et al. In vitro propagation and inducible differentiation of multipotential progenitor cells from human fetal brain. Neuroscience 1997; 76: 1121-8.
25. Wright LS, Li J, Caldwell MA, et al. Gene expression in human neural stem cells: effects of leukemia inhibitory factor. J Neurochem 2003; 86: 179-95.
26. Svendsen CN, Clarke DJ, Rosser AE, et al. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol 1996; 137: 376-88.
27. Svendsen CN, Caldwell MA, Shen J, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol 1997; 148: 135-46.
28. Svendsen CN, ter Borg MG, Armstrong RJE, et al. A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 1998; 85: 141-52.
29. Vescovi AL, Parati EA, Gritti A, et al. Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol 1999; 156: 71-83.
30. Carpenter MK, Cui X, Hu Z-Y, et al. In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol 1999; 158: 265-78.
31. Ostenfeld T, Caldwell MA, Prowse KR, et al. Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp Neurol 2000; 164: 215-26.
32. Kanemura Y, Mori H, Kobayashi S, et al. Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. J Neurosci Res 2002; 69: 869-79.
33. Wright LS, Prowse KR, Wallace K, et al. Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro. Exp Cell Res 2006; 312: 2107-20.
34. Zhang H, Zhao Y, Zhao C, et al. Long-term expansion of human neural progenitor cells by epigenetic stimulation in vitro. Neurosci Res 2005; 51: 157-65.
35. Anderson L, Burnstein RM, He X, et al. Gene expression changes in long term expanded human neural progenitor cells passaged by chopping lead to loss of neurogenic potential in vivo. Exp Neurol 2007; 204: 512-24.
36. Kim HJ, McMillan E, Han F, et al. Regionally Specified Human Neural Progenitor Cells Derived from the Mesencephalon and Forebrain Undergo Increased Neurogenesis Following Overexpression of Ascl1. Stem Cells 2009; 27(2): 390-8.
37. Baghbaderani BA, Mukhida K, Sen A, et al. Expansion of human neural precursor cells in large-scale bioreactors for the treatment of neurodegenerative disorders. Biotechnol Prog 2008; 24: 859-70.
38. Baghbaderani BA, Mukhida K, Sen A, et al. Bioreactor expansion of human neural precursor cells in serum-free media retains neurogenic potential. Biotechnol Bioeng 2010; 105: 823-33.
39. Anderson L, Caldwell MA. Human neural progenitor cell transplants into the subthalamic nucleus lead to functional recovery in a rat model of Parkinson's disease. Neurobiol Dis 2007; 27: 133-140.
40. McBride JL, Behrstock SP, Chen EY, et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol 2004; 475: 211-9.
41. Mukhida K, Baghbaderani BA, Hong M, et al. Survival, differentiation, and migration of bioreactor-expanded human neural precursor cells in a model of Parkinson disease in rats. Neurosurg Focus 2008; 24: E8.
42. Mukhida K, Hong M, Behie LA, et al. Co-grafting with bioreactorexpanded human neural precursor cells enhances survival of fetal dopaminergic transplants in Hemiparkinsonian rodents. Exp Neurol 2006; 198: 582.
43. Mukhida K, Hong M, Miles GB, et al. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in Parkinsonian rats. Brain 2008; 131: 2106-26.
44. Mukhida K, Mendez I, McLeod M, et al. Spinal GABAergic transplants attenuate mechanical allodynia in a rat model of neuropathic pain. Stem Cells 2007; 25: 2874-85.
45. Newman MB, Bakay RAE. Therapeutic Potentials of Human Embryonic Stem Cells in Parkinson's Disease. Neurotherapeutics 2008; 5: 237-251.
46. Luo Y, Kuang SY, Hoffer B. How useful are stem cells in PD therapy? Parkinsonism & Related Disorders 2009; 15: S171-S175.
47. Le Belle JE, Svendsen CN. Stem cells for neurodegenerative disorders: where can we go from here? BioDrugs 2002; 16: 389-401.
48. Gerlach M, Braak H, Hartmann A, et al. Current state of stem cell research for the treatment of Parkinson's disease. J Neurol 2002; 249 Suppl 3: III/33-35.
49. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA 2008; 105: 2883-8.
50. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451: 141-6.
51. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
52. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
53. Cyranoski D. Stem cells: 5 things to know before jumping on the iPS bandwagon. Nature 2008; 452: 406-8.
54. Dhar S, Yoon ES, Kachgal S, et al. Long-term maintenance of neuronally differentiated human adipose tissue derived stem cells. Tissue Eng 2007; 13: 2625-32.
55. Kang SK, Putnam LA, Ylostalo J, et al. Neurogenesis of Rhesus adipose stromal cells. J Cell Sci 2004; 117: 4289-99.
56. Safford KM, Hicok KC, Safford SD, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun 2002; 294: 371-9.
57. Yang LY, Liu XM, Sun B, et al. Adipose tissue-derived stromal cells express neuronal phenotypes. Chin Med J (Engl) 2004; 117: 425-9.
58. Rice CM, Scolding NJ. Autologous bone marrow stem cells- properties and advantages. J Neurol Sci 2008; 265: 59-62.
59. Bouchez G, Sensebé L, Vourc'h P, et al. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int 2008; 52: 1332-42.
60. Kang S-K, Shin M-J, Jung JS, et al. Autologous adipose tissuederived stromal cells for treatment of spinal cord injury. Stem Cells Dev 2006; 15: 583-94.
61. Shimazaki T. Biology and clinical application of neural stem cells. Horm Res 2003; 60(Suppl 3): 1-9.
62. Storch A, Paul G, Csete M, et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 2001; 170: 317-25.
63. Storch A, Schwarz J. Neural stem cells and Parkinson's disease. J Neurol 2002; 249 (Suppl 3): 30-32.
64. Snyder BJ, Olanow CW. Stem cell treatment for Parkinson's disease: an update for 2005. Curr Opin Neurol 2005; 18: 376-85.
65. Suzuki M, Wright LS, Marwah P, et al. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 2004; 101: 3202-7.
66. Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci 2000; 3: 537-44.
67. Parish CL, Castelo-Branco G, Rawal N, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 2008; 118: 149-60.
68. Eaton MJ, Wolfe SQ, Martinez M, et al. Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic spinal cord injury in the rat. J Pain 2007; 8: 33-50.
69. O'Keeffe FE, Scott SA, Tyers P, et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain 2008; 131: 630-41.
70. Svendsen CN, Caldwell MA, Ostenfeld T. Human neural stem cells: isolation, expansion and transplantation. Brain Pathol 1999; 9: 499-513.
71. Villa A, Navarro B, Martinez-Serrano A. Genetic perpetuation of in vitro expanded human neural stem cells: cellular properties and therapeutic potential. Brain Res Bull 2002; 57: 789-94.
72. Jandial R, Singec I, Ames CP, et al. Genetic Modification of Neural Stem Cells. Mol Ther 2008; 16: 450-7.
73. Ostenfeld T, Joly E, Tai YT, et al. Regional specification of rodent and human neurospheres. Brain Res Dev Brain Res 2002; 134: 43-55.
74. Piao JH, Odeberg J, Samuelsson EB, et al. Cellular composition of long-term human spinal cord- and forebrain-derived neurosphere cultures. J Neurosci Res 2006; 84: 471-82.
75. Kallur T, Darsalia V, Lindvall O, et al. Human fetal cortical and striatal neural stem cells generate region-specific neurons in vitro and differentiate extensively to neurons after intrastriatal transplantation in neonatal rats. J Neurosci Res 2006; 84: 1630-44.
76. Horiguchi S, Takahashi J, Kishi Y, et al. Neural precursor cells derived from human embryonic brain retain regional specificity. J Neurosci Res 2004; 75: 817-24.
77. Jain M, Armstrong RJ, Elneil S, et al. Migration and differentiation of transplanted human neural precursor cells. Neuroreport 2003; 14: 1257-62.
78. Kim H-T, Kim I-S, Lee I-S, et al. Human neurospheres derived from the fetal central nervous system are regionally and temporally specified but are not committed Exp Neurol 2006; 199: 222-35.
79. Mukhida K, McLeod M, Hong M, et al. In vitro characterization of bioreactor-expanded human neural progenitor cells for cell restoration strategies. Can J Neurol Sci 2005; 32 (Suppl 1).
80. Bayer SA, Altman J, Russo RJ, et al. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 1993; 14: 83-144.
81. Storch A, Sabolek M, Milosevic J, et al. Midbrain-derived neural stem cells: from basic science to therapeutic approaches. Cell Tissue Res 2004; 318: 15-22.
82. Studer L, Tabar V, McKay R. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998; 1: 290-5.
83. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotech 2006; 24: 185-7.
84. Butler M. Animal cell culture & technology. London: BIOS Scientific Publishers; 2004: 243.
85. Sen A, Behie LA. The development of a medium for the in vitro expansion of mammalian neural stem cells. Can J Chem Eng 1999; 77: 963-72.
86. Nelson AD, Svendsen CN. Low concentrations of extracellular FGF-2 are sufficient but not essential for neurogenesis from human neural progenitor cells. Mol Cell Neurosci 2006; 33: 29-35.
87. Baghbaderani BA. Bioreactor expansion of human brain cells. Chemical and Petroleum Engineering. PhD Thesis. Calgary: University of Calgary; 2008: 686.
88. Kallos MS, Behie LA. Inoculation and growth conditions for highcell- density expansion of mammalian neural stem cells in suspension bioreactors. Biotechnol Bioeng 1999; 63: 473-83.
89. Kallos MS, Behie LA, Vescovi AL. Extended serial passaging of mammalian neural stem cells in suspension bioreactors. Biotechnol Bioeng 1999; 65: 589-99.
90. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 1992; 12: 4565-74.
91. Studer L, Csete M, Lee SH, et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 2000; 20: 7377-83.
92. Freshney RI. Culture of animal cells: a manual of basic technique. New York: Wiley-Liss; 2000 577.
93. Sen A, Kallos MS, Behie LA. New tissue dissociation protocol for scaled-up production of neural stem cells in suspension bioreactors. Tissue Eng 2004; 10: 904-13.
94. Moreira JL, Feliciano AS, Santana PC, et al. Repeated-batch cultures of baby hamster kidney cell aggregates in stirred vessels. Cytotechnology 1994; 15: 337-49.
95. Sen A. Bioreactor Protocols for Neural Stem Cells. Chemical and Petroleum Engineering. PhD Thesis. Calgary: University of Calgary; 2003: 613.
96. Zhu LL, Wu LY, Yew DT, et al. Effects of hypoxia on the proliferation and differentiation of NSCs. Mol Neurobiol 2005; 31: 231-242.
97. Horie N, So K, Moriya T, et al. Effects of Oxygen Concentration on the Proliferation and Differentiation of Mouse Neural Stem Cells In vitro. Cell Mol Neurobiol 2008; 28: 833-45.
98. Santilli G, Lamorte G, Carlessi L, et al. Mild hypoxia enhances proliferation and multipotency of human neural stem cells. PLoS One 2010; 5(1): e8575.
99. Bürgers H, Schelshorn D, Wagner W, et al. Acute anoxia stimulates proliferation in adult neural stem cells from the rat brain. Exp Brain Res 2008; 188: 33-43.
100. Zhang C, Zhu L, Zhao T, et al. Characteristics of Neural Stem Cells Expanded in Lowered Oxygen and the Potential Role of Hypoxia- Inducible Factor-1Alpha. Neurosignals 2006; 15: 259-65.
101. Moreira JL, Alves PM, Aunins JG, et al. Changes in animal cell natural aggregates in suspended batch cultures. Appl Microbiol Biotechnol 1994; 41: 203-9.
102. Moreira JL, Alves PM, Rodrigues JM, et al. Studies of baby hamster kidney natural cell aggregation in suspended batch cultures. Ann N Y Acad Sci 1994; 745: 122-33.
103. Moreira JL, Aunins JG, Carrondo MJ. Hydrodynamics effects on BHK cells grown as suspended natural aggregates. Biotechnol Bioeng 1995; 46: 351-60.
104. Chawla M, Bodnar CA, Sen A, et al. Production of islet-like structures from neonatal porcine pancreatic tissue in suspension bioreactors. Biotechnol Prog 2006; 22: 561-7.
105. Gilbertson JA, Sen A, Behie LA, et al. Scaled-up production of mammalian neural precursor cell aggregates in computer-controlled suspension bioreactors. Biotechnol Bioeng 2006; 94: 783-92.
106. Sen A, Kallos MS, Behie LA. Effects of hydrodynamic on extended cultures of mammalian neural stem cell aggregates in suspension culture. Ind Eng Chem Res 2001; 40: 5350-7.
107. Sen A, Kallos MS, Behie LA. Expansion of mammalian neural stem cells in bioreactors: effect of power input and medium viscosity. Brain Res Dev Brain Res 2002; 134: 103-13.
108. Sen A, Kallos MS, Behie LA. Passaging protocols for mammalian neural stem cells in suspension bioreactors. Biotechnol Prog 2002; 18: 337-45.
109. Youn BS, Sen A, Kallos MS, et al. Large-scale expansion of mammary epithelial stem cell aggregates in suspension bioreactors. Biotechnol Prog 2005; 21: 984-93.
110. Youn BS, Sen A, Behie LA, et al. Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol Prog 2006; 22: 801-10.
111. Kallos MS, Sen A, Behie LA. Large-scale expansion of mammalian neural stem cells: a review. Med Biol Eng Comput 2003; 41: 271-82.
112. Mukhida K, Mendez I, McLeod M, et al. Spinal GABAergic Transplants Attenuate Mechanical Allodynia in a Rat Model of Neuropathic Pain. Stem Cells 2007.
113. Shuler ML, Kargi F. Bioprocess engineering basic concepts. Upper Saddle River: Prentice Hall PTR; 2002: 553.
114. Freyer JP, Sutherland RM. Proliferative and clonogenic heterogeneity of cells from EMT6/Ro multicellular spheroids induced by the glucose and oxygen supply. Cancer Res 1986; 46: 3513-20.
115. Svrcek WY, Mahoney DP, Young BR. A real-time approach to process control. Chichester: John Wiley & Sons Ltd.; 2000: 307.
116. Ravin R, Hoeppner DJ, Munno DM, et al. Potency and Fate Specification in CNS Stem Cell Populations In vitro. Cell Stem Cell 2008; 3: 670-80.
117. Vescovi AL, Galli R, Gritti A. Clonal analyses and cryopreservation of neural stem cell culture. In: Zigova T, Sanberg PR, Sanchez- Ramos JR, eds. Neural stem cells: methods and protocols. Totowa: Humanna Press Inc.; 2002.
118. Reynolds BA, Rietze RL. Neural stem cells and neurospheres-reevaluating the relationship. Nat Methods 2005; 2: 333-6.
119. Seaberg RM, van der Kooy D. Adult rodent neurogenic regions: the ventricular subependyma contains neural stem cells, but the dentate gyrus contains restricted progenitors. J Neurosci 2002; 22: 1784-93.
120. Louis SA, Rietze RL, Deleyrolle L, et al. Enumeration of neural stem and progenitor cells in the neural colony-forming cell assay. Stem Cells 2008; 26: 988-96.
121. Marshall GP, Reynolds BA, Laywell ED. Using the neurosphere assay to quantify neural stem cells in vivo. Curr Pharm Biotechnol 2007; 8: 141-5.
122. Deleyrolle LP, Reynolds BA, Joost Verhaagen EMHIHJWABBGJB, et al. Identifying and enumerating neural stem cells: application to aging and cancer. Progress in Brain Research: Elsevier; 2009: 43-51.
123. Noctor SC, Flint AC, Weissman TA, et al. Neurons derived from radial glial cells establish radial units in neocortex. Nature 2001; 409: 714-20.
124. Ostenfeld T, Svendsen CN. Requirement for Neurogenesis to Proceed through the Division of Neuronal Progenitors following Differentiation of Epidermal Growth Factor and Fibroblast Growth Factor-2-Responsive Human Neural Stem Cells Stem Cells 2004; 22: 798-811.
125. Pruszak J, Sonntag KC, Aung MH, et al. Markers and Methods for Cell Sorting of Human Embryonic Stem Cell-Derived Neural Cell Populations. Stem Cells 2007; 25: 2257-68.
126. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000; 97: 14720-5.
127. Coskun V, Wu H, Blanchi B, et al. CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci USA 2008; 105: 1026-31.
128. Gottschling S, Saffrich R, Seckinger A, et al. Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism. Stem Cells 2007; 25: 798-806.
129. Shakibaei M, Csaki C, Mobasheri A. Diverse roles of integrin receptors in articular cartilage. Adv Anat Embryol Cell Biol 2008; 197: 1-60.
130. Ievdokimova N. [Hyaluronic acid, receptor CD44, and their role in diabetic complications]. Ukr Biokhim Zh 2008; 80: 5-44.
131. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information- rich system. Eur J Cell Biol 2006; 85: 699-715.
132. Yasuda M, Nakano K, Yasumoto K, et al. CD44: functional relevance to inflammation and malignancy. Histol Histopathol 2002; 17: 945-950.
133. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cellmatrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 2006; 20: 1045-54.
134. Hirata H, Murakami Y, Miyamoto Y, et al. ALCAM (CD166) is a surface marker for early murine cardiomyocytes. Cells Tissues Organs 2006; 184: 172-80.
135. Gattenlohner S, Stuhmer T, Leich E, et al. Specific Detection of CD56 (NCAM) Isoforms for the Identification of Aggressive Malignant Neoplasms with Progressive Development. Am J Pathol 2009; 174: 1160-71.
136. Mukhida K, Hong M, Mendez I. Tissue Transplantation for Parkinson's Disease. In: Textbook of Stereotactic and Functional Neurosurgery Eds. Andres M. Lozano, Philip L. Gildenberg and Ronald R. Tasker. Springer Berlin Heidelberg, 2009, pp 1691-1717.
137. Wang X, Li X, Wang K, et al. Forskolin cooperating with growth factor on generation of dopaminergic neurons from human fetal mesencephalic neural progenitor cells. Neurosci Lett 2004; 362: 117-21.
138. Ye W, Shimamura K, Rubenstein J, Hynes M, Rosenthal A. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 1998; 93: 755-66.
139. Riaz SS, Jauniaux E, Stern GM, Bradford HF. The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro. Brain Res Dev Brain Res 2002; 136: 27-34.
140. Chung S, Shin B-S, Hwang M, et al. Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro. Stem Cells 2006b; 24: 1583-93.
141. Ciccolini F, Svendsen F. Fibroblast growth factor 2 (FGF-2) promotes acquisition of epidermal growth factor (EGF) responsiveness in mouse striatal precursor cells: identification of neural precursors responding to both EGF and FGF-2. J Neurosci 1998; 18(19): 7869-80.
142. Hitoshi S, Seaberg RM, Koscik C, et al. Primitive neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of Notch signaling. Genes Dev 2004; 18(15): 1806-11.
143. Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19(12): 1129-33.
144. Hong S, Kang UJ, Isacson O, Kim KS. Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. J Neurochem 2007; 104(2): 316-24.
145. Qian X, Shen Q, Goderie SK, et al. Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells. Neuron 2000; 28: 69-80.
146. Song HJ, Stevens CF, Gage FH. Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nature Neuroscience 2002; 5(5): 438-45.
147. Chung S, Shin BS, Hedlund E, et al. Genetic selection of sox1GFPexpressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem 2006; 97: 1467-80.
148. Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000; 28(1): 31-40.
149. Kim D-W, Chung S, Hwang M, et al. Stromal cell-derived inducing activity, Nurr1 and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells 2006; 24(3): 557-67.
150. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000; 18: 675-9.
151. Björklund LM, Sánchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99(4): 2344-9.
152. Cho MS, Lee YE, Kim JY, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2008; 105(9): 3392-7.
153. Kim J-H, Auerbach JM, Rodríguez-Gómez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418(July): 50-6.
154. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101(34): 12543-8.
155. Takahashi J, Takagi Y, Saiki H. Transplantation of embryonic stem cell-derived dopaminergic neurons in MPTP-treated monkeys. Methods Mol Biol 2009; 482: 199-212.
156. Jain M, Armstrong RJE, Tyers P, Barker RA, Rosser AE. GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol 2003; 182: 113-23.
157. Qian X, Davis AA, Goderie SK, Temple S. FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron 1997; 18: 81-93.
158. Emsley JG, Mitchell BD, Kempermann G, Macklis JD. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol 2005; 75: 321-41.
159. Fricker RA, Carpenter MK, Winkler C, Greco C, Gates MA, Björklund A. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci 1999; 19: 5990-6005.
160. Herrera DG, Garcia-Verdugo JM, Alvarez-Buylla A. Adult-derived neural precursors transplanted into multiple regions in the adult brain. Annals Neurol 1999; 46: 867-77.
161. Shihabuddin LS, Horner PJ, Ray J, Gage FH. Adult spinal cord stem cells generate neurons after transplantation in the adult dentate gyrus. J Neurosci 2000; 20: 8727-35.
162. Englund U, Björklund A, Wictorin K. Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Brain Res Dev Brain Res 2002; 134: 123-41.
163. Englund U, Fricker-Gates RA, Lundberg C, Björklund A, Wictorin K. Transplantation of human neural progenitor cells into the neonatal rat brain: extensive migration and differentiation with longdistance axonal projections. Exp Neurol 2002; 173: 1-21.
164. Schuurmans C, Guillemot F. Molecular mechanisms underlying cell fate specification in the developing telencephalon. Curr Opin Neurobiol 2002; 12: 26-34.
165. Toda H, Takahashi J, Mizoguchi A, Koyano K, Hashimoto N. Neurons generated from adult rat hippocampal stem cells form functional glutamatergic and GABAergic synapses in vitro. Exp Neurol 2000; 165(1): 66-76.
166. Nishino H, Hida H, Takei N, Kumazaki M, Nakajima K, Baba H. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum. Exp Neurol 2000; 164: 209-14.
167. Yang M, Donaldson AE, Jiang Y, Iacovitti L. Factors influencing the differentiation of dopaminergic traits in transplanted neural stem cells. Cell Mol Neurobiol 2003; 23: 851-64.
168. Maciaczyk J, Singec I, Maciaczyk D, Klein A, Nikkhah G. Restricted spontaneous in vitro differentiation and region-specific migration of long-term expanded fetal human neural precursor cells after transplantation into the adult rat brain. Stem Cells Dev 2009; 18: 1043-58.
169. Berninger B, Guillemot F, Götz M. Directing neurotransmitter identity of neurones derived from expanded adult neural stem cells. Eur J Neurosci 2007; 25: 2581-90.
170. Milosevic A, Noctor SC, Martinez-Cerdeno V, Kriegstein AR, Goldman JE. Progenitors from the postnatal forebrain subventricular zone differentiate into cerebellar-like interneurons and cerebellar- specific astrocytes upon transplantation. Mol Cell Neurosci 2008; 39: 324-34.
171. Zhang H, Wang Y, Zhao Y, Yin Y, Xu Q, Xu Q. Immortalized human neural progenitor cells from the ventral telencephalon with the potential to differentiate into GABAergic neurons. J Neurosci Res 2008; 86: 1217-26.
172. Alenina N, Bashammakh S, Bader M. Specification and differentiation of serotonergic neurons. Stem Cell Reviews 2006; 2: 5-10.
173. Riaz SS, Bradford HF. Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease. Prog Neurobiol 2005; 76: 257-78.
174. Carvey PM, Ling ZD, Sortwell CE, et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol 2001; 171(1): 98-108.
175. Cai J, Donaldson A, Yang M, German MS, Enikolopov G, Iacovitti L. The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells 2009; 27(1): 220-9.
176. Friling S, Andersson E, Thompson LH, et al. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci USA 2009; 106(18): 7613-8.
177. Smidt MP, Asbreuk CH, Cox JJ, Chen H, Johnson RL, Burbach JP. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat Neurosci 2000; 3(4): 337-41.
178. Andersson EK, Irvin DK, Ahlsiö J, Parmar M. Ngn2 and Nurr1 act in synergy to induce midbrain dopaminergic neurons from expanded neural stem and progenitor cells. Exp Cell Res 2007; 313: 1172-80.
179. Brederlau A, Correia AS, Anisimov SV, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006; 24(6): 1433-40.
180. Paul G, Meissner W, Rein S, Harnack D, Winter C, Hosmann K, Morgenstern R, Kupsch A. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004; 185: 272-80.
181. Yang D, Zhang Z-J, Oldenburg M, Ayala M, Zhang S-C. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008; 26(1): 55-63.
182. Isacson O, Kordower JH. Future of cell and gene therapies for Parkinson's disease. Ann Neurol 2008; 64 (suppl): S122-S138.
183. Morizane A, Takahashi J, Takagi Y, Sasai Y, Hashimoto N. Optimal conditions for in vivo induction of dopaminergic neurons from embryonic stem cells through stromal cell-derived inducing activity. J Neurosci Res 2002; 69: 934-9.
184. Morizane A, Li JY, Brundin P. From bench to bed: the potential of stem cells for the treatment of Parkinson's disease. Cell Tissue Res 2008; 331(1): 323-36.
185. Shim JW, Park CH, Bae YC, et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells 2007; 25: 1252-62.
186. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by cocultured with telomerase-immortalized midbrain astrocytes. Nat Med 2006; 12(11): 1259-68.
187. Blanchard V, Raisman-Vozari R, Vyas S, et al. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res 1994; 22(1-4): 29-38.
188. Isacson O, Björklund LM, Schumacher JM. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol 2003; 53(suppl 3): S135-S148.
189. Strecker RE, Sharp T, Brundin P, Zetterström T, Ungerstedt U, Björklund A. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987; 22: 169-78.
190. Thompson L, Barraud P, Andersson E, Kirik D, Björklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci 2005; 25(27): 6467-77.
191. Zetterström T, Brundin P, Gage FH, et al. In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 1986; 362: 344-9.
192. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344(10): 710-9.
193. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
194. Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52(5): 628-34.
195. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007; 27(30): 8011-22.
196. Carlsson T, Carta M, Muñoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009; 132: 319-35.
197. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats. Brain 2007; 130: 1819-33.
198. Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Serotonindopamine interaction in the induction and maintenance of LDOPA- induced dyskinesias. Prog Brain Res 2008; 172: 465-78.
199. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008; 131: 3380-94.
200. Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009; 219(1): 298-307
201. Hynes M, Rosenthal A. Specification of dopaminergic and serotonergic neurons in the vertebrate CNS. Cur Opin Neurobiol 1999; 9: 26-36.
202. Hedlund E, Pruszak J, Ferree A, et al. Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Stem Cells 2007; 25: 1126-35.
203. Johansson S, Strömberg I. Guidance of dopaminergic neuritic growth by immature astrocytes in organotypic cultures of rat fetal ventral mesencephalon. J Comp Neurol 2002; 443: 237-49.
204. Hall VJ, Li J-Y, Brundin P. Restorative cell therapy for Parkinson's disease: a quest for the perfect cell. Seminars in cell and developmental biology 2007; 18: 859-69.
205. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif 2008; 41 (Suppl 1): 94-114.
206. Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol 2008; 85: 407-432.
207. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson's disease. Expert Reviews in Neurotherapeutics 2008; 8: 1125-39.
208. Peterson AL, Nutt JG. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008; 5: 270-280.
209. Bowenkamp KE, Hoffman AF, Gerhardt GA, et al. Glial cell linederived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Compar Neurol 1995; 355: 479-489.
210. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995; 672: 104-111.
211. Rosenblad C, Martinez-Serrano A, Björklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998; 82: 129-37.
212. Sauer H, Rosenblad C, Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 1995; 92: 8935-9.
213. Shults CW, Kimber T, Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. NeuroReport 1996; 7: 627-31.
214. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-5.
215. Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997; 282: 1396-401.
216. Gouhier C, Chalon S, Aubert-Pouessel A, et al. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse 2002; 44: 124-31.
217. Jollivet C, Aubert-Pouessel A, Clavreul A, et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 2004; 25: 933-42.
218. Bilang-Bleuel A, Revah F, Colin P, et al. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997; 94: 8818-23.
219. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-41.
220. Kozlowski DA, Connors B, Tillerson JL, Schallert T, Bohn MC. Delivery of a GDNF gene into the substantia nigra after a progress sive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 2000; 166: 1-15.
221. Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S. Adenoviral vector mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 1997; 777: 153-60.
222. Kordower JH, Palfi S, Chen EY, Ma SY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-26.
223. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, doubleblind trial of glial cell line-derived neurotrophic factor in PD. Neurology 2003; 60: 69-73.
224. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-95.
225. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005; 11: 703-4.
226. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-66.
227. Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 2007; 106(4): 614-20.
228. Patel NK, Bunnage M, Plaha P, Svensden CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005; 57: 298-302.
229. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005; 102: 216-22.
230. Ebert A, Beres AJ, Barber AE, Svendsen CN. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol 2008; 209: 213-23.
231. Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line-derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002; 177: 461-74.
232. Breysse N, Carlsson T, Winkler C, Björklund A, Kirik D. The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. J Neurosci 2007; 27(22): 5849-56.
233. Emborg ME, Ebert AD, Moirano J, et al. GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. Cell Transplant 2008; 17: 383-95.
234. Borgal L, Hong M, Sadi D, Mendez I. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro. Neuroscience 2007; 147: 712-9.
235. Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience 2006; 141: 521-31.
236. Jakobsson J, Rosenqvist N, Marild K, Agoston DV, Lundberg C. Evidence for disease-regulated transgene expression in the brain with use of lentiviral vectors. J Neurosci Res 2006; 84: 58-67.
237. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996; 8: 1408-14.
238. Wallace BA, Ashkan K, Heise CE, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007; 130: 2129-45.
239. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-105.
240. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002; 298: 425-9.
241. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleusmediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998; 44: S175-S188.
242. Bachoud-Lévi AC, Gaura V, Brugières P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurology 2006; 5: 303-9.
243. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58: 687-95.
244. Thompson K. Transplantation of GABA-producing cells for seizure control in models of temporal lobe epilepsy. Neurotherapeutics 2009; 6: 284-94.
245. Dawson L, Bateman-House AS, Agnew DM, et al. Safety issues in cell-based intervention trials. Fertility and Sterility 2003; 80(5): 1077-85.
246. Li J-Y, Christophersen NS, Hall V, Soulet D, Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends in Neurosci 2008; 31: 146-53.
247. Khademhosseini A, Vacanti J, Langer R. Tissue Engineering: Next Generation Tissue Constructs and Challenges to Clinical Practice. Sci Am 2009; 300: 64-71.
248. Soen Y, Mori A, Palmer TD, et al. Exploring the regulation of human neural precursor cell differentiation using arrays of signaling microenvironments. Mol Syst Biol 2006; 2.